TERN-701
Chronic Myeloid Leukemia (CML)
Phase 1Currently Enrolling
Key Facts
Indication
Chronic Myeloid Leukemia (CML)
Phase
Phase 1
Status
Currently Enrolling
Company
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biotech focused on reimagining known biology to advance superior small-molecule therapies, primarily in oncology. The company's strategy centers on starting with de-risked, clinically validated mechanisms and innovating to accelerate the development of potentially best-in-class treatments. With a seasoned leadership team of experienced drug hunters, Terns is rapidly advancing its lead CML candidate, TERN-701, through clinical trials while maintaining a pipeline of other promising oncology programs.
View full company profileTherapeutic Areas
Other Chronic Myeloid Leukemia (CML) Drugs
| Drug | Company | Phase |
|---|---|---|
| ELVN-001 | Enliven Therapeutics | Phase 1b |
| Imatinib | Natco Pharma | Approved |